The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders

Klausen, Mette Kruse, Thomsen, Morgane, Wortwein, Gitta, Fink‐Jensen, Anders·2022·British Journal of Pharmacology
DOI 10.1111/bph.15677

Cited by (258)

Items 201–258 of 258

  1. Improvement of Compulsive Shopping on Tirzepatide
    Anna I. Guerdjikova, Lorene L. Walter, Susan L. McElroy · 2026 · Journal of Clinical Psychopharmacology
  2. Cellular scaling laws in the mammalian brain
    Fei Chen, Evan Z. Macosko · 2026 · Cell
  3. Антиаддиктивный потенциал двойного агониста инкретиновых рецепторов тирзепатида в тесте на эмоциональное переедание, вызванное внутримозговой самостимуляцией
    Nikolai S. Dedanishvili, Сарнг Саналович Пюрвеев, Андрей Андреевич Лебедев, Андрей Глебович Васильев, Петр Дмитриевич Шабанов, Дмитрий Анатольевич Лебедев · 2026 · Pediatrician (St Petersburg)
  4. GLP-1 Receptor Agonists: Emerging Indications, Limitations, and Future Directions
    Simran Kaur, Liriam Campos Hevia, Diane Lee, Haroon Mesdaq, Joleen Wong, Fatimetou Diallo, Shreya Anil, Nadia Gharibyar, Sarah Gharibyar · 2026 · Pharmacology &amp Pharmacy
  5. GLP-1 is associated with perfectionism in Swedish women with anorexia nervosa, independent of BMI
    Sofia Elm, Suzanne Petersson, Martin Carlsson, Lars H. Brudin, Ína Marteinsdóttir, Pär Wanby · 2026 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
  6. GLP-1 drugs may fight addiction across every major substance, according to a study of 600,000 people
    Ziyad Al-Aly · 2026
  7. El Ozempic y otros fármacos GLP-1 podrían combatir la adicción a todo tipo de sustancias
    Ziyad Al-Aly · 2026
  8. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder
    Alyx Meilinger, Michael A. Campbell, Hannah M. Reynolds, Augustine S. Chavez · 2026 · Journal of Primary Care & Community Health
  9. Connecting the Dots: Neurobiological Interplay Between Type 2 Diabetes and Alzheimer’s Disease
    Analia Foncea-Bitrán, Cristián Barros-Osorio, Francisca Arriaza, Catalina Ramírez-López, Lina María Ruíz, Marlen Barreto, Fernando C. Ortíz, Francisca Cornejo, Gonzalo I. Gómez · 2026 · International Journal of Molecular Sciences
  10. Rôle des interactions mitochondrie-réticulum endoplasmique dans le contrôle de la sécrétion du Glucagon-Like Peptide 1 (GLP-1) et altérations au cours du diabète de type 2
    Alexandre Humbert · 2024 · theses.fr (ABES)
  11. Considering incentives for aggression
    Abigail A. Marsh, Marla Dressel, Naomi Michel Nero, Ah. Yeong Kim, Samantha Perlstein · 2026 · Aggression and Violent Behavior
  12. Oral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence
    Kurt M. Hong, SUELA S. SULO, William Wang, Miranda Kim, Lucas Hong, Kirk W. Kerr, Linlin Fan, Dominique Williams · 2026 · Diabetes Metabolic Syndrome and Obesity
  13. Alterations in glucose and insulin resistance following stress and alcohol cues predict alcohol craving in those with AUD and obesity: A preliminary study
    Zachary M. Harvanek, Verica Milivojevic, Rachel Hart, Rajita Sinha · 2026 · Alcoholism Clinical and Experimental Research
  14. Ceftriaxone has a similar effect on astrocytic and neuronal GLT-1 distribution after mild traumatic brain injury
    Yana Naumenko, Borys Olifirov, Irada Yuryshinetz, T. A. Pivneva · 2026 · Biochemical and Biophysical Research Communications
  15. Multisystem regulation of reward and addiction: beyond the dopaminergic system
    Óscar Arias-Carrión, Emmanuel Ortega‐Robles, Mario Treviño, Magdalena Guerra‐Crespo, Elı́as Manjarrez, Ernst Pöppel · 2026 · Frontiers in Pharmacology
  16. Application and interpretation of non-invasive testing in MetALD
    Wah‐Kheong Chan, Ken Liu, George Boon‐Bee Goh, Vincent Wai‐Sun Wong · 2026 · Metabolism and Target Organ Damage
  17. GLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: PROMISE FOR A NEW TREATMENT APPROACH
    Jakub Fidelus, Klaudia Jurkowska, Dominika Dutkiewicz, Julia Madrzak, Olga Endler, Mikołaj Dybicz, Marianna Ciastoń, Magdalena Filuk, Julia Czerniewska, Marta Handzel · 2026 · International Journal of Innovative Technologies in Social Science
  18. Chapter 7. Pharmacological and Other Biological Treatments for Tobacco Use Disorder
    2024 · American Psychiatric Association Publishing eBooks
  19. Letter to the Editor from Bhaduri et al.: “GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia”
    Rossella Cannarella, Calogero Ae, Riccardo Polosa · 2026 · Endocrine
  20. Glucagon-like Peptide-1 Receptor Agonists and Their Potential Role in the Treatment of Substance Use Disorders: A Narrative Review
    Adam Caplin, Ronald Ian Fraser · 2026 · The Canadian Journal of Addiction
  21. Ventral Tegmental Area Amylin Receptors Mediate Maladaptive Responses to Social Stress
    Megan Fox, Alexandria E. Ostman, Laura Murdaugh, Hajra Sohail, Annalisa Montemarano, Arial Briones · 2026 · Research Square
  22. GLP‐1 Agonist Attenuates Nicotine Reward‐Related Behavior by Regulating the Prepro‐Orexin in the Hypothalamus and Prepro‐Glucagon in the Nucleus Tractus Solitarius
    Mahardian Rahmadi, Chrismawan Ardianto, Ratchanee Rodsiri, D. (Devina Ingrid) Anggraini, A. P. S. A. Firdaussy, I Nengah Budi Sumartha, Ahmad Dzulfikri Nurhan · 2026 · Behavioural Neurology
  23. Interpretable machine learning for rare events: an inverse probability weighted application to understanding glucagon-like peptide-1 receptor agonists use and incident alcohol-related disorder
    Rinoj Gautam, Hao Wang, Bo Zhou, Rolake A. Neba, Usha Sambamoorthi · 2026 · Alcohol and Alcoholism
  24. GLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: A NARRATIVE REVIEW OF THERAPEUTIC POTENTIAL AND WELL-BEING OUTCOMES
    Nina Polek, Małgorzata Sikorska, Patrycja Mularczyk, Wojciech Łysoniewski, Artur Marcysiak, Tomasz Mruzek, Magdalena Kiełbasiewicz, Karolina Zawadzka · 2026 · International Journal of Innovative Technologies in Social Science
  25. GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders
    José Seijas‐Amigo, Ángel Salgado‐Barreira, Sonia Eiras, Susana Arias-Rivas, Gemma Rodríguez-Carnero, José Ramón González‐Juanatey · 2026 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  26. A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders
    Indrani Devi Sarma, Krishna P Biswas, Prerna Jagdish, K Praveen, Kashif Akhtar Ahmed, Dibyajyoti Saikia · 2026 · Cureus
  27. Glucagon‐Like Peptide‐1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms
    Céline Eiden, Ghjulia Chautard, Anne Batisse, Aurélie Aquizerate, Amandine Luquiens, Hélène Donnadieu, Jean‐Luc Faillie, Hélène Peyrière · 2026 · Fundamental and Clinical Pharmacology
  28. Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform
    Jacopo Ciaffi, Roberto Caporali, Francesco Ursini · 2026 · Lara D. Veeken
  29. Association of GLP‐1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort
    Benjamin D. Tyndall, Angela Gasdaska, M. Daniel Brannock, Edward A. Preble, Melissa L McPheeters, Laura Haak Marcial, Ariba Huda, Josephine Egan, Tamara R. Litwin, Jennifer Adjemian et al. · 2026 · Alcoholism Clinical and Experimental Research
  30. Response to the letter to the editor entitled “Glucodependence in Cardiorenometabolic Disease: Naming the Problem”
    Luxcia Kugathasan, Marcel H.A. Muskiet, Vikas S. Sridhar, David Z.I. Cherney · 2026 · Kidney International Reports
  31. Patients Taking Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) Presenting to the Emergency Department, 2017–2025
    Theodore C. Chan, Jesse J. Brennan, James P. Killeen, Edward M. Castillo · 2026 · Emergency Care and Medicine
  32. Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
    Sandro La Vignera, Rosita Angela Condorelli · 2026 · Biomedicines
  33. GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction
    Joshua Reitz, Daniel B. Rosoff, Pál Pacher, Falk W. Lohoff · 2026 · Biological Psychiatry Global Open Science
  34. GLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials
    Javad Heshmati, Salma Mahmoodianfard, Ethan Raizman, Aidan Abraham, Hassan R. Mir · 2026 · Tobacco Induced Diseases
  35. A Serial Mediation Analysis of Delay Discounting and Remission in Substance Use Disorders Recovery
    Ghada Nusair, Daniel A. R. Cabral, Roberta Freitas Lemos, Rose P. Kaur, Liqa N. Athamneh, Garrett Posey, Warren Kurt Bickel, Allison N. Tegge · 2026 · Substance Use & Misuse
  36. Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions
    María José Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan · 2026 · Clinical Pharmacology & Therapeutics
  37. Could Patients Using Glucagon-like Peptide-1 Receptor Agonists Be Experiencing Less Postoperative Pain?
    Ion A. Hobai, Burel Goodin · 2026 · Anesthesia & Analgesia
  38. THE ROLE OF GLP-1RECEPTOR AGONIST IN MODULATING ALCOHOL INTAKE: INSIDES FROM SEMAGLTIDE THERAPY
    M Anusha, Padakantinaga Harshitha, Banda jashwanth, Vaddera Prashanthi · 2025 · International Journal of Research in Pharmacology & Pharmacotherapeutics
  39. Treating, Masking, or Mismeasuring? A Measurement-First Reframing of GLP-1 Receptor Agonists Across the Eating-Disorder Spectrum
    Maja Sosnowska, Leszek Czupryniak · 2026 · Endocrines
  40. GLP-1 and dual GIP/GLP-1 receptor agonists’ psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill–informed, systematic, evaluation
    Fabrizio Schifano, Maria Antonietta De Luca, Stefania Bonaccorso, Davide Arillotta, G Floresta, G. Martinotti, Gabriele Duccio Papanti, John Corkery, Stefania Chiappini, Amira Guirguis · 2026 · Current Psychiatry Reports
  41. L’agonismo recettoriale di GLP-1 e GLP-1/GIP nel sistema edonico: dalla regolazione del comportamento alimentare alle prospettive neurologiche
    Emmanuele Capobianco, Federica Delfini, Federica Perazza, Fabiana Sbrega, Maria Letizia Petroni, Silvia Garelli · 2026 · L Endocrinologo
  42. International consensus recommendations for smoking cessation in type 2 diabetes from the DiaSmokeFree Working group
    Magdalena Walicka, Cristina Russo, Antonio Ceriello, Jacob George, Davide Campagna, Anoop Misra, Giusy Rita Maria La Rosa, Roberta Sammut, Riccardo Polosa · 2026 · Diabetes Research and Clinical Practice
  43. Emergency Department Management of Nicotine Use: A White Paper Prepared for the American Academy of Emergency Medicine
    J. Moore, Brittany Cesar, Joshua J. Davis, Emma R. Furlano, Zachary D. Repanshek, Scott G. Weiner, Reuben J. Strayer · 2026 · Journal of Emergency Medicine
  44. Role of Incretin Glucagon like Peptide 1 in Hypoglycemia
    Kiran Dahiya, Kumud Dhankhar, Rakesh Dhankhar · 2026 · Indian Journal of Medical Biochemistry
  45. The gut-liver-brain axis in alcohol use disorder: The emerging role of bile acid dysregulation
    Xuan Lin, Xiaojie Yu, Xue Bai, Hafiz Muhammad Isha, Chuansheng Wang, Ruilin Zhang, Fan Yang · 2026 · Behavioural Brain Research
  46. Central nervous system effects of GLP-1 receptor agonists: A systematic review of human neuroimaging studies
    Leyla R. Brucar, Kylee M. Miller, Nora D. Volkow · 2026 · Neuroscience & Biobehavioral Reviews
  47. GLP-1 RECEPTOR AGONISTS IN METABOLIC HEALTH: EXPANDING APPLICATIONS, WEIGHT MANAGEMENT, AND EMERGING SAFETY CONSIDERATIONS
    Natalia Kostecka, Katarzyna Otrębska, Aleksandra Szredzka, Dominika Lewandowska, Aleksandra Makulec, Aleksandra Jóźwik-Szymańska, Laura Mikula, Zuzanna Bogdan-Groszyk, Jan Kucharski · 2026 · International Journal of Innovative Technologies in Social Science
  48. Alcohol consumption: from biochemistry to behavior, health, and beyond
    Evgeny Pechkovsky, Boris Kershengoltz, Valentin V. Vlassov, Vasiliy Vlassov, Andrey Turchinovich · 2026 · Frontiers in Toxicology
  49. BEYOND WEIGHT LOSS: EMERGING EXTRA-METABOLIC APPLICATIONS OF GLP-1 RECEPTOR AGONISTS IN CARDIOVASCULAR, RENAL, NEUROLOGICAL AND INFLAMMATORY DISORDERS: A NARRATIVE REVIEW
    Paulina Bigda, Zuzanna Rafałowska, Stanisław Rutz, A. Wojtala, Julia Kret, Aleksandra Wyrostkiewicz, Aleksander Sadkowski, Jan Gdula, Lilianna Zielińska, Michał Szpunar et al. · 2026 · International Journal of Innovative Technologies in Social Science
  50. GLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS
    Karolina Klusek, Michal Batory, Jakub Jakubowski, Karol Kraska, Nadzieja Krasucka, Aleksandra Zynkowska, Aleksandra Magdalena Skrzyniarz, Maria Kiełbus, Julia Oziębło, Magdalena Kijowska · 2026 · International Journal of Innovative Technologies in Social Science
  51. Early neuroendocrine signatures of polyendocrine metabolic ovarian syndrome risk: Pubertal programming, social brain signals, and novel therapeutic targets
    Seda Hanife Oğuz, Bülent Okan Yıldız · 2026 · Journal of Neuroendocrinology
  52. Incretin Mimetics and Alcohol‐Related Outcomes: A Structured Narrative Review
    Christopher Goodyear, Eric Mensah, Autumn L. Stewart-Lynch, Jordan R. Covvey · 2026 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  53. Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review
    Pugazhendi Inban, Ashita Agrawal, Kakarala Rushika, Halla Tariq, Andy Thai, Dastan Kudaiarov, Priyadarshi Prajjwal, Jobby John · 2026 · Disease-a-Month
  54. Patient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation
    Lori Uscher‐Pines, Jessica Sousa, Alisa B. Busch, Ateev Mehrotra, Andrew J. Muzyk, Dominic Hodgkin, Shelly F. Greenfield, Haiden A. Huskamp · 2026 · JAMA Psychiatry
  55. Influence of GLP‐1‐Based Pharmacotherapies on Eating Behavior, Appetite, and Energy Intake in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis
    Clarissa A. Dakin, Jordan D. Beaumont, Beverley O’Hara · 2026 · Obesity Reviews
  56. EXPANDING THERAPEUTIC HORIZONS OF GLP-1 RECEPTOR AGONISTS: FROM METABOLIC REGULATION TO NEUROPROTECTION IN ALZHEIMER’S DISEASE AND ADDICTION DISORDERS – A COMPREHENSIVE REVIEW
    Karolina Reczka, Zuzanna Zalewska, Julia Szymkowiak, Maria Woźniak · 2026 · International Journal of Innovative Technologies in Social Science
  57. From metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders
    Fares Qeadan, Erin Fanning Madden, Mark R. Burge · 2026 · Expert Review of Clinical Pharmacology
  58. Beyond appetite: GLP-1 receptor drugs at the crossroads of pain, opioid reward, and overdose risk
    Ovie Martin Albert · 2026 · Therapeutic Advances in Psychopharmacology